Structured diagnostic and treatment approach versus the usual primary care approach in patients with gastroesophageal reflux disease: A cluster-randomized multicenter study

Journal of Clinical Gastroenterology

Volumn 47, Issue 7, 2013, Pages e65-e73

  Bergquist, Henrik ^a   Agréus, Lars ^a   Tillander, Lotta ^a   Johnsson, Folke ^a   Sörngård, Heléne ^b   Sjöstedt, Svante ^b   Hellström, Per M ^b  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

Author keywords

Gastroesophageal reflux disease; Health economics; Health related quality of life; Primary care; Randomized trial

Indexed keywords

ADULT; ARTICLE; CLINICAL PATHWAY; CLINICAL PRACTICE; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DIAGNOSTIC PROCEDURE; FEMALE; FOLLOW UP; GASTROESOPHAGEAL REFLUX; HEALTH CARE COST; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RESOURCE ALLOCATION; TREATMENT OUTCOME;

ADULT; AGED; CLUSTER ANALYSIS; FEMALE; FOLLOW-UP STUDIES; GASTROESOPHAGEAL REFLUX; HUMANS; MALE; MIDDLE AGED; PRIMARY HEALTH CARE; PROTON PUMP INHIBITORS; QUALITY OF LIFE; QUESTIONNAIRES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84880718233     PISSN: 01920790     EISSN: 15392031     Source Type: Journal    
DOI: 10.1097/MCG.0b013e31827d7782     Document Type: Article

References (28)

1. Ronkainen J, Aro P, Storskrubb T, et al.High prevalence of gastroesophageal reflux symptoms and esophagitis with or without symptoms in the general adult Swedish population: a Kalixanda study report.Scand J Gastroenterol. 2005;40:275-285.
2. Delaney BC.Review article: prevalence and epidemiology of gastro-oesophageal reflux disease.Aliment Pharmacol Ther. 2004;20 suppl 8 2-4.
3. Agréus L, Borgquist L.The cost of gastro-oesophageal reflux disease, dyspepsia and peptic ulcer disease in Sweden.Pharmacoeconomics. 2002;20:347-355.
4. Hungin AP, Hill C, Raghunath A.Systematic review: frequency and reasons for consultation for gastro-oesophageal reflux disease and dyspepsia.Aliment Pharmacol Ther. 2009;30:331-342.
5. Sontag SJ, Sonnenberg A, Schnell TG, et al.The long-term natural history of gastroesophageal reflux disease.J Clin Gastroenterol. 2006;40:398-404.
6. Agréus L.The epidemiology of functional gastrointestinal disorders.Eur J Surg. 1998;164 suppl 583 60-66.
7. Vakil N, van Zanten SV, Kahrilas P, et al.The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus.Am J Gastroenterol. 2006;101:1900-1920 quiz 1943.
8. Wiklund I.Review of the quality of life and burden of illness in gastroesophageal reflux disease.Dig Dis. 2004;22:108-114.
9. Johnsson F, Hatlebakk JG, Klintenberg AC, et al.Symptom-relieving effect of esomeprazole 40 mg daily in patients with heartburn.Scand J Gastroenterol. 2003;38:347-353.
10. Malfertheiner P, Lind T, Willich S, et al.Prognostic influence of Barrett’s oesophagus and Helicobacter pylori infection on healing of erosive gastro-oesophageal reflux disease (GORD) and symptom resolution in non-erosive GORD: report from the ProGORD study.Gut. 2005;54:746-751.
11. McQuaid KR, Laine L.Early heartburn relief with proton pump inhibitors: a systematic review and meta-analysis of clinical trials.Clin Gastroenterol Hepatol. 2005;3:553-563.
12. Bytzer P.What makes individuals with gastroesophageal reflux disease dissatisfied with their treatment?Clin Gastroenterol Hepatol. 2009;7:816-822.
13. Jones R, Junghard O, Dent J, et al.Development of the GerdQ, a tool for the diagnosis and management of gastro-oesophageal reflux disease in primary care.Aliment Pharmacol Ther. 2009;30:1030-1038.
14. Shaw MJ, Talley NJ, Beebe TJ, et al.Initial validation of a diagnostic questionnaire for gastroesophageal reflux disease.Am J Gastroenterol. 2001;96:52-57.
15. Shaw M, Dent J, Beebe T, et al.The reflux disease questionnaire: a measure for assessment of treatment response in clinical trials.Health Qual Life Outcomes. 2008;6:31.
16. Wahlqvist P, Carlsson J, Stalhammar NO, et al.Validity of a work productivity and activity impairment questionnaire for patients with symptoms of gastro-esophageal reflux disease (WPAI-GERD)--results from a cross-sectional study.Value Health. 2002;5:106-113.
17. Wahlqvist P, Medin J, Karlsson M, et al.Responsiveness to change and construct validity of the work productivity and activity impairment questionnaire for gastroesophageal reflux disease (WPAI:GERD) in Swedish patients.Value Health. 2009;12:A60.
18. EQ-5D: a standardized instrument for use as a measure of health outcome. Available at:. Accessed January 1, 2012.
19. Dolan P.Modeling valuations for EuroQol health states.Med Care. 1997;35:1095-1108.
20. van Pinxteren B, Sigterman KE, Bonis P, et al.Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease. In: The Cochrane Library; 2009. Available at:. Cochrane Database Syst Rev. 2010;11:CD002095.
21. Tunis SR, Stryer DB, Clancy CM.Practical clinical trials: increasing the value of clinical research for decision making in clinical and health policy.JAMA. 2003;290:1624-1632.
22. Ofman JJ, Dorn GH, Fennerty MB, et al.The clinical and economic impact of competing management strategies for gastro-oesophageal reflux disease.Aliment Pharmacol Ther. 2002;16:261-273.
23. Jonasson C, Moum B, Bang C, et al.Randomised clinical trial: a comparison between a GerdQ-based algorithm and an endoscopy-based approach for the diagnosis and initial treatment of GERD.Aliment Pharmacol Ther. 2012;35:1290-1300.
24. Lacy BE, Chehade R, Crowell MD.A prospective study to compare a symptom-based reflux disease questionnaire to 48-h wireless pH monitoring for the identification of gastroesophageal reflux.Am J Gastroenterol. 2011;106:1604-1611.
25. Moayyedi P, Armstrong D, Hunt RH, et al.The gain in quality-adjusted life months by switching to esomeprazole in those with continued reflux symptoms in primary care: EncomPASS—a cluster-randomized trial.Am J Gastroenterol. 2010;105:2341-2346.
26. Raghunath AS, Hungin AP, Mason J, et al.Symptoms in patients on long-term proton pump inhibitors: prevalence and predictors.Aliment Pharmacol Ther. 2009;29:431-439.
27. Jones R, Horbach S, Sander P, et al.Heartburn in patients with gastro-oesophageal reflux disease in Germany and Sweden: a study on patients’ burden of disease.Pharmacoeconomics. 2003;21:1091-1102.
28. Eldridge SM, Ashby D, Feder GS, et al.Lessons for cluster randomized trials in the twenty-first century: a systematic review of trials in primary care.Clin Trials. 2004;1:80-90.